Revolution Medicines Inc (RVMD)
$46.44
+0.88
(+1.93%)▲
Performance
- $45.96$46.75$46.44
1.03%
Downside
Day's Volatility :1.69%
Upside
0.66%
- $15.44$48.61$46.44
66.75%
Downside
52 Weeks Volatility :68.24%
Upside
4.46%
Returns
| Period | Revolution Medicines Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 26.7% | 6.5% | 0.0% |
6 Months | 64.18% | 7.1% | 0.0% |
1 Year | 80.01% | 9.8% | 0.0% |
3 Years | 62.83% | 14.2% | -20.2% |
Highlights
Market Capitalization | 7.7B |
Book Value | $10.46 |
Earnings Per Share (EPS) | -3.84 |
Wall Street Target Price | 59.85 |
Profit Margin | 0.0% |
Operating Margin TTM | -11550.31% |
Return On Assets TTM | -22.11% |
Return On Equity TTM | -36.17% |
Revenue TTM | 4.6M |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | -95.19999999999999% |
Gross Profit TTM | -217.7M |
EBITDA | -522.0M |
Diluted Eps TTM | -3.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.24 |
EPS Estimate Next Year | -3.75 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.78 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 28.88%
Technicals Summary
Sell
Neutral
Buy
Revolution Medicines Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Revolution Medicines Inc | 18.58% | 64.18% | 80.01% | 62.83% | 57.65% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Revolution Medicines Inc | NA | NA | NA | -3.24 | -0.36 | -0.22 | NA | 10.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Revolution Medicines Inc | Buy | $7.7B | 57.65% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Revolution Medicines Inc
Decreasing Revenue
Revenue is down for the last 4 quarters, 15.33M → 742.0K (in $), with an average decrease of 60.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -161.53M → -116.00M (in $), with an average increase of 39.3% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 123.7%
Institutional Holdings
Vanguard Group Inc
8.94%Wellington Management Company LLP
8.92%BlackRock Inc
7.46%Baker Bros Advisors LP
4.58%Farallon Capital Management, L.L.C.
4.55%Nextech Invest AG
3.82%
Corporate Announcements
Revolution Medicines Inc Earnings
Revolution Medicines Inc’s price-to-earnings ratio stands at None
Read More
Company Information
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Organization | Revolution Medicines Inc |
Employees | 411 |
CEO | Dr. Mark A. Goldsmith Ph.D. |
Industry | Health Technology |
Discover More
Outfront Media Inc.
$46.44
+1.93%
Blackrock Short Duration Bond Etf
$46.44
+1.93%
Moog Inc
$46.44
+1.93%
Edgio Inc.
$46.44
+1.93%
Invesco S&p 500 Momentum Etf
$46.44
+1.93%
Silicon Laboratories Inc
$46.44
+1.93%
Helmerich & Payne, Inc.
$46.44
+1.93%
Crane Nxt Co
$46.44
+1.93%
Liberty Global Plc - Class C Shares
$46.44
+1.93%